Skip to content

Northland Capmk Analysts Decrease Earnings Estimates for Alvotech (NYSE:ALVO)

Alvotech (NYSE:ALVO – Get Ranking) – Equities researchers at Northland Capmk reduce their FY2026 earnings per share estimates for shares of Alvotech in a analysis be aware issued to traders on Thursday, November seventeenth. Northland Capmk analyst C. Byrnes now expects that the corporate will publish earnings of $2.10 per share for the yr, down from their earlier estimate of $2.40. The consensus estimate for Alvotech’s present full-year earnings is ($1.24) per share.

ALVO has been the subject of a number of different analysis experiences. Citigroup lowered Alvotech from a “purchase” ranking to a “promote” ranking and lowered their worth goal for the inventory from $12.00 to $5.00 in a analysis report on Tuesday, September sixth. Morgan Stanley initiated protection on Alvotech in a analysis report on Wednesday, September seventh. They set an “equal weight” ranking and a $10.00 worth goal on the inventory.

Alvotech Buying and selling Up 5.3%

NYSE ALVO opened at $6.20 on Monday. The corporate has a 50 day transferring common worth of $6.67. Alvotech has a 52 week low of $5.20 and a 52 week excessive of $14.04.

Institutional Inflows and Outflows

Plenty of institutional traders have lately made adjustments to their positions in ALVO. Gamco Buyers INC. ET AL acquired a brand new place in Alvotech within the 2nd quarter valued at $110,000. UBS Group AG acquired a brand new place in Alvotech within the 2nd quarter valued at $112,000. Jane Road Group LLC acquired a brand new place in Alvotech within the 2nd quarter valued at $337,000. Millennium Administration LLC acquired a brand new place in Alvotech within the 2nd quarter valued at $431,000. Lastly, Sculptor Capital LP acquired a brand new place in Alvotech within the 2nd quarter valued at $6,612,000. 62.50% of the inventory is owned by institutional traders and hedge funds.

Alvotech Firm Profile

(Get Ranking)

Alvotech, by means of its subsidiaries, develops and manufactures biosimilar medicines for sufferers worldwide. It affords biosimilar merchandise within the therapeutic areas of autoimmune, eye, and bone problems, in addition to most cancers. The corporate’s lead program is AVT02, a excessive focus formulation biosimilar to Humira to deal with numerous inflammatory situations, together with rheumatoid arthritis, psoriatic arthritis, Crohn’s illness, ulcerative colitis, plaque psoriasis, and different indications; AVT04, a biosimilar to Stelara to deal with numerous inflammatory situations comprising psoriatic arthritis, Crohn’s illness, ulcerative colitis, plaque psoriasis, and different indications; AVT06, a biosimilar to Eylea to deal with numerous situations, corresponding to age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is within the pre-clinical section to deal with forestall bone fracture, spinal twine compression, and the necessity for radiation or bone surgical procedure in sufferers with sure kinds of most cancers, in addition to forestall bone loss and improve bone mass.

Featured Articles

This instantaneous information alert was generated by narrative science expertise and monetary information from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Alvotech, you will wish to hear this.

MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Alvotech wasn’t on the record.

Whereas Alvotech at present has a “Maintain” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The 5 Shares Right here

.

Leave a Reply

Your email address will not be published. Required fields are marked *